Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP, Head of R&D | March 02, 2023 | March 06, 2023 |
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 10, 2026 | June 11, 2026 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Chief Medical Officer | February 14, 2020 | February 19, 2020 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | SVP & Chief Medical Officer | October 09, 2016 | October 11, 2016 |
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | August 20, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 290,794 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Sale · Disposed 5,074 · Balance 290,794 F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
Bolt Biotherapeutics, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-06-09 | Direct | 5,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Gossamer Bio, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,500 |
Reported balance
After 2020-02-14 transaction · row 1
1 source rowRow 1 · 2020-02-14 · Grant · Acquired 46,500 · Balance 46,500 F1: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2030-02-14 | Direct | 71,500 |
Reported balance
After 2020-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-14 · Grant · Acquired 71,500 · Balance 71,500 F2: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
F2: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
OncoMed Pharmaceuticals Inc
Report date October 09, 2016 · Filed October 11, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,440 |
Reported balance
After 2016-10-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-10-09 · Grant · Acquired 12,500 · Balance 34,440 F1: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2: Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
F2: Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016.
Pyxis Oncology, Inc.
Report date August 20, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.12 · Expires 2036-08-20 | Direct | 46,000 |
Reported balance
After 2026-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 46,000 · Balance 46,000 F1: The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2030-09-01 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 34,084 · Balance 0 F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2031-02-12 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-23 · Disposition to issuer · Disposed 20,489 · Balance 0 F2: This exercise price was reported incorrectly as $4.49 in a Form 3/A filed on August 24, 2023. F3: The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F2: This exercise price was reported incorrectly as $4.49 in a Form 3/A filed on August 24, 2023.
F3: The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F4: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 20, 2026 22:18 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001193125-26-359525 · ownership.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2036-08-20 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001193125-26-294708 · ownership.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 357,461 Underlying: Common Stock · 35,000 shares Expires 2033-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | SaleCommon Stock | 35,000 | $3.06 | $107,100.00 |
DisclosureSEC source: 0001193125-26-294708 · ownership.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,741 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025. F2 · price: Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4. F3 · price: The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | Exercise / conversionCommon Stock | 35,000 | $1.60 | $56,000.00 |
DisclosureSEC source: 0001193125-26-294708 · ownership.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:12 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001193125-26-267546 · ownership.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 21:18 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 45,867 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001193125-26-124388 · ownership.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,867 Underlying: Common Stock · 45,867 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $6.40 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 8 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F7 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 7 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F7 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,000 | Not disclosed Strike: $7.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 6 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2035-04-30 F5 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,000 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 5 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2035-04-30 F5 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 849 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 4 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 849 shares Expires 2034-09-02 F4 · price: The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 849 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 849 shares Expires 2034-09-02 F4 · price: The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 2,500 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2034-09-02 F2 · price: The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,500 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321156 · ownership.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2034-09-02 F2 · price: The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control. Read SEC document |
| May 27, 2025 Filed Jul 2, 2025 20:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 1,100 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0000950170-25-092941 · ownership.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F1 · derivative.exercise_price: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F2 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. F1 · derivative.underlying_shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · balance_after: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. Read SEC document |
| May 01, 2025 Filed May 6, 2025 01:28 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0000950170-25-063886 · ownership.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-04-30 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/6th of the Shares will vest upon the Reporting Person completing each month of continuous service following May 1, 2025. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 13:00 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 36,979 | $0.98 Strike: $0.98 | $36,239.42 |
DisclosureSEC source: 0000950170-25-048898 · ownership.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,979 Underlying: Common Stock · 36,979 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 16:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 16,984 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001415889-24-023005 · form4-09062024_040947.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,984 Underlying: Common Stock · 16,984 shares Expires 2034-09-02 F2 · derivative.exercise_date: The shares subject to this option shall vest in full on the date immediately preceding the date of the Issuer's next annual stockholder meeting for so long as the Reporting Person is serving as a director of the Issuer on such date; provided, however that the option will vest in full upon a change in control. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 16:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001415889-24-023005 · form4-09062024_040947.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-09-02 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 20:32 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 38,741 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038102 · ownership.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,741 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 23:04 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 392,461 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-23-050613 · doc4.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,461 Underlying: Common Stock · 392,461 shares Expires 2033-09-22 F1 · derivative.exercise_date: These stock options vest in three equal annual installments beginning on the first anniversary of August 23, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:29 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-047446 · doc4.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F4 · price: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F4 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:29 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 20,489 | Not disclosed Strike: $4.59 | Not disclosed |
DisclosureSEC source: 0001209191-23-047446 · doc4.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,489 shares Expires 2031-02-12 F2 · derivative.exercise_price: This exercise price was reported incorrectly as $4.49 in a Form 3/A filed on August 24, 2023. F3 · price: The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F3 · derivative.exercise_date: The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:29 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 34,084 | Not disclosed Strike: $4.59 | Not disclosed |
DisclosureSEC source: 0001209191-23-047446 · doc4.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,084 shares Expires 2030-09-01 F1 · price: The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 17,250 | Not disclosed Strike: $15.37 | Not disclosed |
DisclosureSEC source: 0001209191-23-047384 · doc4.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,250 Underlying: Common Stock · 17,250 shares Expires 2032-09-29 F2 · price: On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent. F1 · derivative.exercise_date: The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 3,534 | Not disclosed Strike: $26.61 | Not disclosed |
DisclosureSEC source: 0001209191-23-047384 · doc4.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,534 Underlying: Common Stock · 3,534 shares Expires 2031-02-12 F2 · price: On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent. F1 · derivative.exercise_date: The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 5,879 | Not disclosed Strike: $26.61 | Not disclosed |
DisclosureSEC source: 0001209191-23-047384 · doc4.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,879 Underlying: Common Stock · 5,879 shares Expires 2030-09-01 F2 · price: On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent. F1 · derivative.exercise_date: The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,074 | $3.63 | $18,403.40 |
DisclosureSEC source: 0001567619-23-004537 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,794 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 317,987 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001140361-23-010100 · form4.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,987 Underlying: Common Stock · 317,987 shares Expires 2033-02-28 F2 · derivative.exercise_date: 1/36th of the shares subject to the stock option vest and become exercisable each month, with the initial installment vesting on April 1, 2023, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 141,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010100 · form4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,868 F1 · shares: These restricted stock units vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2023, subject to the reporting person's continuous service. "Company Quarterly Vesting Date" means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,124 | $4.49 | $5,047.88 |
DisclosureSEC source: 0001140361-22-042381 · form4.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,540 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,218 | $4.49 | $14,448.82 |
DisclosureSEC source: 0001140361-22-042381 · form4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,664 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:12 UTC | Apexigen, Inc. APGN · Entity 110214 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001209191-22-051935 · doc4.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,124 | $5.03 | $20,760.22 |
DisclosureSEC source: 0001140361-22-030300 · form4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,882 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| May 17, 2022 Filed May 19, 2022 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,873 | $5.32 | $20,596.61 |
DisclosureSEC source: 0001140361-22-019981 · form4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,006 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 17, 2022 and May 18, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 147,573 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001140361-22-007765 · form4.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,573 Underlying: Common Stock · 147,573 shares Expires 2032-02-28 F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,221 | $9.86 | $21,890.18 |
DisclosureSEC source: 0001140361-22-007765 · form4.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,879 F2 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 78,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-007765 · form4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,100 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001567619-22-004499 · doc1.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,500 Underlying: Common Stock · 5,000 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,000 | $16.00 | $80,000.00 |
DisclosureSEC source: 0001567619-22-004499 · doc1.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,594 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,000 | $9.58 | $47,900.00 |
DisclosureSEC source: 0001567619-22-004499 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:47 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001567619-22-000568 · doc1.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 5,000 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:47 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,000 | $16.01 | $80,050.00 |
DisclosureSEC source: 0001567619-22-000568 · doc1.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,594 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:47 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,000 | $9.58 | $47,900.00 |
DisclosureSEC source: 0001567619-22-000568 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001567619-21-021583 · doc1.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,500 Underlying: Common Stock · 5,000 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,000 | $17.94 | $89,688.50 |
DisclosureSEC source: 0001567619-21-021583 · doc1.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,594 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.78 to $18.135. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,000 | $9.58 | $47,900.00 |
DisclosureSEC source: 0001567619-21-021583 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,199 | $17.12 | $37,640.06 |
DisclosureSEC source: 0001567619-21-020777 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,594 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001567619-21-019331 · doc1.xml · derivative · entry 3 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,500 Underlying: Common Stock · 5,000 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,000 | $16.41 | $82,050.00 |
DisclosureSEC source: 0001567619-21-019331 · doc1.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,793 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.